.Attribute Medicine, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medicine conjugate (ADC) tisotumab vedotin caused enhanced progression-free as well as general survival, resulting in FDA approval as well as a new therapy option for individuals.